Introduction
============

Blood is in the truest sense the elixir of life. It contains a part of the extracellular fluid along with a wide variety of other constituents which are indispensable for proper functioning and survival of human life. From providing nutrients, limiting pathogens, perfusing and ventilating organs, clotting wounds, removal of toxins and chemicals, and dissemination of hormones and drugs throughout the body it performs a pivotal role in body defense and survival. Presence of organisms in blood can give rise to different clinical scenarios. Clinical presentation ranges from benign transient bacteremia with little or no symptoms to fulminant septic shock with high mortality. [@BR_1]

Bacteremia or fungemia denotes the presence of viable bacteria or fungi in the blood with or without clinical symptoms. Systemic inflammatory response syndrome (SIRS) is defined by the presence of two or more acute findings (tachycardia, leukocytosis, or leukocytopenia, fever or hypothermia, tachypnea). Combination of SIRS and bacteremia is known as sepsis which is a host systemic response to infection. Sepsis with additional acute organ dysfunction due to documented or suspected infection is known as severe sepsis. Septic shock is defined as severe sepsis with hypotension which is unresponsive to fluid resuscitation. [@BR_2] Blood stream infections (BSI) are a major cause of morbidity and mortality and are among the most common health care-associated infections. With an attributable mortality rate of 15%, it is an eminent cause of death worldwide. [@BR_1]

Presence of microbes in blood whether continuously, intermittently, or transiently is a grave risk to every organ of the body. Early diagnosis plays a crucial role in managing BSI and hence prompt detection of such infections is a critical function of clinical microbiology laboratories. Blood culture is a vital tool for the detection of BSI and is the gold standard for bacteremia detection. Initial antimicrobial empirical therapy being very imperative in BSI, must be based on the knowledge of the bacterial profile and their sensitivity patterns. [@JR_3] Irrational use of drugs leads to an increase of multidrug-resistant bugs and thus worsens the management of the infections. Prevalence and susceptibility patterns of microorganisms vary according to the geography and use of antibiotics in different health care settings. There is paucity of similar reports with regard to disease burden from Northeast India, and more so from Meghalaya. This region is unique with respect to its ethnicity, geographical location, topography, climatic condition unlike the rest of the country. The current study intends to report the prevalence, bacteriological analysis of microorganisms, and antimicrobial susceptibility profiles of blood culture isolates and other auxiliary variables in a tertiary health care center in Northeast India.

Materials and Methods
=====================

The present study is a 5-year retrospective observational analysis of blood culture isolates received in the Department of Microbiology of the hospital from January 2009 to December 2013. Necessary Ethics Committee Approval was obtained for the study.

Sample Collection
-----------------

Blood specimens were obtained at bedside either by a trained phlebotomist or by nursing staff from wards and critical care units. The skin was disinfected with 2% chlorhexidine. Approximately 5 to 10 mL of blood was collected from adult patients, 1 to 5 mL from pediatric patients, and 1 to 2 mL from neonates. The antecubital and median cubital fossa were the preferred sampling sites using a needle and syringe. The blood samples from the central vein catheters were obtained from needleless caps that have been disinfected with 70% isopropyl alcohol, allowed to dry, and wiped with sterile gauze prior to obtaining the sample.

Sample Processing
-----------------

Blood for culture was collected from 5,867 clinically suspected bacteremia cases under strict aseptic precautions. They were inoculated into conventional blood culture bottles containing Brain Heart Infusion broths (1:10 dilution). These were incubated aerobically at 37°C, observed for turbidity every morning, and manually agitated for aeration for 7 complete days. [@JR_4] Regular blind subcultures were done at the completion of day 2 and day 7 of aerobic incubation. Subcultures were done on MacConkey agar, 5% Sheep blood agar, and chocolate agar as and when turbidity was noticed. Specimens were discarded after 7 days of unsuccessful aerobic incubation. [@BR_5] Any growth obtained was processed and identified by Gram staining, colony morphology, and standard biochemical tests. Antibiotic susceptibility testing was done according to Kirby Bauer disk diffusion method and interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines. [@BR_6] Positive growths were further critically analyzed based on the criteria to be agents of bacteremia, fungemia, and contaminants. [@JR_7] [@JR_8] [@JR_9] The data were manually compiled and analyzed critically for the study. The following strains were used as quality control strains:

1.  *Staphylococcus aureus* (ATCC 25923)

2.  *Escherichia coli* (ATCC 25922)

3.  *Pseudomonas aeruginosa* (ATCC 27853)

Results
=======

The present study involves 5,867 continuous samples received from different wards and intensive care units (ICUs) of the hospital. Among them, 740 isolates showed positive aerobic bacterial growth and 669 (11.40%) of them were recognized pathogens. However, blood bank surveillance revealed 11 pathogens and 17 contaminants. Finally, 658 (11.2%) isolates were recovered from patients as incriminating microorganisms responsible for bacteremia/fungemia. More males suffered from bacteremia than females with a gender ratio skewed at 1.4:1, ( [Supplementary Table S1](#SM00005-001){ref-type="supplementary-material"} , online only). The mean age of patients was 33.67 ± 23 years (range 0--85 years). Bulk of the specimens were sent from Medicine, Pediatric wards apart from critical care units. Data including the most common clinical syndromes leading to bacteremia/fungemia and the corresponding distribution of the microbial agents responsible are depicted in [Table 1](#TB_1){ref-type="table"} . Cerebrovascular accidents and their subsequent complications were the leading cause for BSIs. Contamination in blood culture was documented in 71 (1.21%) isolates in the present study. Most of them were from blood bank and pediatric ICU. A detailed analysis of contaminants obtained from different sections of hospital is presented in [Table 2](#TB_2){ref-type="table"} . Among 658 isolates recovered from patients, the spectrum of microbes included 436 (66.3%) gram-negative bacilli (GNB), 195 (29.6%) gram-positive cocci (GPC), 15 gram-negative cocci, 1 gram-positive bacilli, and 11 yeasts. Isolation of GNBs was significantly higher ( *p* \< 0.001) than other groups of organisms. Within GNBs, *Klebsiella pneumoniae* (28.67%) was the dominant isolate obtained followed by *Acinetobacter baumannii* (22.47%) and *Pseudomonas aeruginosa* (14.45%). Eleven isolates of *Salmonella spp* . and one isolate of *Hemophilus influenzae* were also recovered. As a group, *Enterobacteriaceae* comprised half of all GNBs and 32.67% of total pathogens recovered. Among GPCs isolated, *S. aureus* (65.6%) was the dominant organism followed by *Enterococcus spp.* (15.38%) and *Streptococcus* spp. (11.8%). One-third of *Enterococcus* *spp* . isolates carried high-level aminoglycoside resistance (HLAR) genes. *Streptococcus pneumoniae* was recovered from seven bacteremic patients. Of them, five were children younger than 9 years and two elderly older than 50 years. They were most likely severe cases of pneumococcal pneumonia causing bacteremia. Fifteen isolates of *Neisseria meningitidis* were recovered from the study. *Neisseria meningitidis* is a dreaded organism considering the capability of this organism to rapidly deteriorate relatively benign bacteremia into fulminant bacteremia and septic shock. Worth mentioning here is that all these cases were recovered during an outbreak between November 2008 and April 2009.

###### Most common clinical syndromes with incriminating microbes' distribution

  Sl. no.   Name of initial clinical diagnosis/syndrome   Microbes isolated   *Staphylococcus spp.*   *Enterococcus spp.*   *Klebsiella spp.*   *Escherichia coli*   *Pseudomonas spp.*   *Acinetobacter spp.*   *Enterobacter spp.*   *Nonfermenting GNB*   *Neisseria meningitidis*   *Salmonella spp.*   Others
  --------- --------------------------------------------- ------------------- ----------------------- --------------------- ------------------- -------------------- -------------------- ---------------------- --------------------- --------------------- -------------------------- ------------------- --------
  1         Severe pneumonia                              12                  4                                                                 2                    2                    2                                                                                                                 2
  2         DM with complications                         21                  2                       1                     6                   7                                         1                      2                     1                                                                    1
  3         Tuberculous meningitis                        15                  3                                             5                                        1                    4                                            2                                                                    
  4         Bacteremia and sepsis                         14                  5                       1                                         3                    2                    2                                            1                                                                    
  5         Seizures and epilepsy                         08                  3                                                                                                           3                      1                                                                                          1
  6         Rheumatic disease with complications          14                                          5                     3                   1                    1                    2                                            1                                                                    1
  7         Prematurity                                   9                   2                                             2                                        3                    1                      1                                                                                          
  8         Postoperative infection (general surgical)    27                  4                                             3                   6                    8                    3                                            2                                                                    1
  9         Post exploratory laparotomy                   23                  2                       1                     4                                                             9                                            6                                                                    1
  10        Meningitis and meningoencephalitis            28                  4                       1                     2                                        1                    1                      1                     3                     13                                             2
  11        Intracranial hemorrhage                       16                  1                                             11                                       1                                           3                                                                                          
  12        Hepatic encephalopathy                        8                                                                 1                   1                    3                                           1                                                                                          2
  13        CKD with complications                        26                  1                                             8                   4                    3                    10                                                                                                                
  14        Acute pancreatitis                            10                  2                                             5                                        2                                                                                                                                      1
  15        CVA with complications                        49                  3                       1                     18                                       5                    15                     3                     1                                                                    3
  16        Enteric fever                                 6                                           1                                                                                   1                                                                                             4                   
  17        COPD with complications                       8                   2                       1                                                                                   4                                                                                                                 1
  18        Fever                                         11                  3                                                                 1                    2                                                                 1                                                4                   
  19        Fever under evaluation                        38                  13                      1                                                              4                    6                      2                     3                                                1                   8
  20        Uncertain diagnosis                           22                  5                       2                     7                   1                    1                    3                                                                  1                          1                   1
  21        CHD with CCF                                  8                   4                                             1                                                             1                                                                                                                 2
  22        CIDP with autonomic neuropathy                8                                                                 3                   1                    1                    3                                                                                                                 
  23        Hypertensive disorders with complications     13                  1                       2                                                              1                    8                                                                                                                 1

###### Details of samples, pathogens, and contaminants from different wards

  Department                  Total samples   Negative culture samples   Organisms isolated   Pathogen yield   Contamination                        
  --------------------------- --------------- -------------------------- -------------------- ---------------- --------------- ----------- -------- ----------
  Blood bank                  181             153                        28                   15.47            11              6.08        17       9.39
  Cardiology                  326             315                        11                   3.37             10              3.07        1        0.31
  Medicine                    1,236           1,162                      74                   5.99             64              5.18        10       0.81
  CTVS                        147             127                        20                   13.61            19              12.93       1        0.68
  Dialysis unit               8               6                          2                    25.00            2               25.00       0        0.00
  Otolaryngology              16              16                         0                    0.00             0               0.00        0        0.00
  General surgery             40              38                         2                    5.00             1               2.50        1        2.50
  Coronary care unit          172             155                        17                   9.88             17              9.88        0        0.00
  ICU                         1,170           800                        370                  31.62            362             30.94       8        0.68
  Neurology                   60              59                         1                    1.67             1               1.67        0        0.00
  Obstetrics and gynecology   143             134                        9                    6.29             8               5.59        1        0.70
  Oncology                    42              42                         0                    0.00             0               0.00        0        0.00
  Ophthalmology               2               1                          1                    50.00            0               0.00        1        50.0
  Orthopedics                 45              39                         6                    13.33            5               11.11       1        2.22
  Pediatrics                  911             836                        75                   8.23             65              7.14        10       1.10
  Pediatric ICU               1,239           1,122                      117                  9.44             98              7.91        19       1.53
  Private ward                84              79                         5                    5.95             4               4.76        1        1.19
  Urology                     45              43                         2                    4.44             2               4.44        0        0.00
  **Total**                   **5,867**       **5,127**                  **740**              **12.61**        **669**         **11.40**   **71**   **1.21**

Fungemia confirmed in 11 cases were mostly *Candida spp.* A single case of bacteremia by *Listeria monocytogenes* was also detected in a 2-year-old child who presented with acute gastroenteritis. Comparison of isolation rates of organisms on different days of incubation shows that chances of isolation of microbes within the second day of incubation was significantly ( *p* \< 0.001) higher than other days. The distribution of different isolates and groups recovered with each passing day of incubation is presented in [Table 3](#TB_3){ref-type="table"} . Significant isolation ( *n* = 242, 36.7%) of organisms was obtained subsequent to turbidity detection on the second day. This was followed by higher detection of organisms on the third day ( *n* = 115) and first day ( *n* = 89) of incubation. A total of 331 isolates were recovered after detecting turbidity within the first 48 hours of aerobic incubation compared with 327 isolates of organisms which were recovered when incubation was continued beyond 48 hours till 7 days. Interestingly, both *K. pneumoniae* and *Escherichia coli* were consistently isolated better in significant proportions ( *p* \< 0.001) within the first 48 hours. Almost 73.8 and 80% isolates of *K. pneumoniae* and *E. coli* , respectively were detected within initial 48 hours. Concurrently, organisms which have significantly higher chances of recovery after initial 48 hours include *Candida spp* . ( *p* = 0.006), *N. meningitidis* ( *p* = 0.017), *Salmonella paratyphi* ( *p* = 0.044), methicillin-resistant *S. aureus* (MRSA; *p* \< 0.001), and methicillin-sensitive *S. aureus* (MSSA, *p* = 0.024). However, there was no significant difference between number of organisms isolated within or beyond 48 hours till 7 days. A comprehensive distribution frequency table shows different microbes with their growth patterns at 48 hours and at 7 days ( [Table 4](#TB_4){ref-type="table"} ). A comparison of data about the source of blood collection shows that *A. baumannii* and *K. pneumoniae* have significantly higher chances ( *p* \< 0.05) of isolation from central line catheters compared with peripheral venipuncture, while chances of recovery of isolates from peripheral venipuncture were observed to be significantly higher for *Candida spp., Enterococcus* (HLAR) spp., *Salmonella typhi, S. aureus, S. pneumoniae* , and other α and β hemolytic *Streptococcus spp* . A description about the same attribute is depicted in [Table 5](#TB_5){ref-type="table"} . The antibiotic susceptibility patterns for GPCs and GNBs were interpreted in accordance to prevalent CLSI guidelines [@BR_6] and are represented in [Tables 6](#TB_6){ref-type="table"} [7](#TB_7){ref-type="table"} , respectively.

###### Day-wise distribution of blood stream pathogens recovered

                                      Day 1   Day 2   Day 3   Day 4   Day 5   Day 6   Day 7   Total
  ----------------------------------- ------- ------- ------- ------- ------- ------- ------- ---------------
  *Staphylococcus aureus (MSSA)*      5       20      13      12      4       7       6       67
  *Staphylococcus aureus (MRSA)*      4       7       17      13      9       8       3       61
  *CoNS*                              0       3       2       1       0       1       0       7
  *Enterococcus spp.*                 3       9       4       0       0       3       1       20
  *Enterococcus spp. (HLAR)*          2       4       0       1       1       0       2       10
  α *-hemolytic Streptococcus spp.*   6       4       3       4       0       1       0       18
  β *-hemolytic Streptococcus spp.*   0       2       2       0       0       0       1       5
  *Streptococcus pneumoniae*          0       4       1       2       0       0       0       7
  Total                                                                                       ***n* = 195**
  **Gram-negative bacilli**                                                                   
  *Escherichia coli*                  11      17      4       1       1       1       0       35
  *Klebsiella oxytoca*                2       2       1       0       0       0       0       5
  *Klebsiella pneumoniae*             29      63      13      5       9       1       5       125
  *Nonfermenter GNB*                  3       11      1       6       6       4       4       35
  *Acinetobacter baumannii*           14      39      12      12      9       2       10      98
  *Acinetobacter lwoffii*             1       8       3       0       5       1       4       22
  *Proteus spp.*                      0       0       2       0       0       1       0       3
  *Proteus mirabilis*                 0       2       0       0       0       0       0       2
  *Morganella morganii*               1       1       0       0       0       0       0       2
  *Enterobacter spp.*                 3       10      2       0       1       5       4       25
  *Citrobacter freundii*              0       2       1       0       0       0       0       3
  *Citrobacter diversus*              0       2       1       0       0       1       0       4
  *Pseudomonas spp.*                  0       0       0       0       1       0       1       2
  *Pseudomonas aeruginosa*            3       26      16      10      1       4       3       63
  *Salmonella paratyphi*              0       0       4       0       0       0       0       4
  *Salmonella enteritidis*            1       0       0       0       0       0       0       1
  *Salmonella typhi*                  0       2       1       0       0       1       2       6
  *Hemophilus influenzae*             0       1       0       0       0       0       0       1
  Total                                                                                       ***n* = 436**
  **Others**                                                                                  
  *Neisseria meningitidis*            1       2       8       0       1       1       2       15
  *Listeria monocytogenes*            0       0       0       0       1       0       0       1
  *Candida spp.*                      0       1       4       0       4       2       0       11
  **GRAND TOTAL**                     89      242     115     67      53      44      48      **658**

###### Comparison of yield of pathogens after aerobic incubation between 48 h vs. 7 d

                                     Day       Total     Significance test                               
  ---------------------------------- --------- --------- ------------------- --------- --------- ------- ----------
  *Acinetobacter baumannii*          53        16.01%    45                  13.76%    98        0.81    0.417
  *Acinetobacter lwoffii*            9         2.72%     13                  3.98%     22        −0.9    0.37
  *Candida spp.*                     1         0.30%     10                  3.06%     11        −2.76   0.006
  *Citrobacter spp.*                 4         1.21%     3                   0.92%     7         0.36    0.716
  *CoNS*                             3         0.91%     4                   1.22%     7         −0.4    0.692
  *Enterobacter spp.*                13        3.93%     12                  3.67%     25        0.17    0.863
  *Enterococcus spp.*                12        3.63%     8                   2.45%     20        0.88    0.378
  *Enterococcus spp. (* HLAR)        6         1.81%     4                   1.22%     10        0.62    0.536
  *Escherichia coli*                 28        8.46%     7                   2.14%     35        3.66    \< 0.001
  *Hemophilus influenzae*            1         0.30%     0                   0.00%     1         −1      0.317
  *Klebsiella oxytoca*               4         1.21%     1                   0.31%     5         1.34    0.18
  *Klebsiella pneumoniae*            92        27.79%    33                  10.09%    125       5.95    \< 0.001
  *Listeria monocytogenes*           0         0.00%     1                   0.31%     1         −1      0.317
  *Morganella morganii*              2         0.60%     0                   0.00%     2         1.42    0.156
  *Neisseria meningitidis*           3         0.91%     12                  3.67%     15        −2.38   0.017
  *Nonfermenter* GNB                 14        4.23%     21                  6.42%     35        −1.25   0.21
  *Proteus spp.*                     2         0.60%     3                   0.92%     5         −0.46   0.644
  *Pseudomonas aeruginosa*           29        8.76%     34                  10.40%    63        −0.71   0.476
  *Pseudomonas spp.*                 0         0.00%     2                   0.61%     2         −1.42   0.156
  *Salmonella enteritidis*           1         0.30%     0                   0.00%     1         1       0.317
  *Salmonella paratyphi*             0         0.00%     4                   1.22%     4         −2.01   0.044
  *Salmonella Typhi*                 2         0.60%     4                   1.22%     6         −0.83   0.404
  *Staphylococcus aureus* (MRSA)     11        3.32%     50                  15.29%    61        −5.39   \< 0.001
  *Staphylococcus aureus* (MSSA)     25        7.55%     42                  12.84%    67        −2.25   0.024
  *Streptococcus pneumoniae*         4         1.21%     3                   0.92%     7         0.36    0.716
  α-hemolytic *Streptococcus spp.*   10        3.02%     8                   2.45%     18        0.45    0.651
  β-hemolytic *Streptococcus spp.*   2         0.60%     3                   0.92%     5         −0.46   0.644
  **Total**                          **331**   100.00%   **327**             100.00%   **658**           

###### Comparative data about blood stream infections from central line vs. peripheral linesa

                                          Line   Total    Significance test                            
  --------------------------------------- ------ -------- ------------------- -------- ----- --------- ----------
  *Acinetobacter baumannii*               26     27.96%   59                  14.94%   85    2.6100    0.0090
  *Acinetobacter lwoffii*                 3      3.23%    12                  3.04%    15    0.0900    0.9260
  *Candida spp.*                          0      0.00%    5                   1.27%    5     −2.2500   0.0240
  *Citrobacter spp.*                      0      0.00%    2                   0.51%    2     −1.4200   0.1560
  *CoNS*                                  1      1.08%    3                   0.76%    4     0.2700    0.7850
  *Enterobacter spp.*                     3      3.23%    16                  4.05%    19    −0.4000   0.692
  *Enterococcus spp.*                     3      3.23%    12                  3.04%    15    0.0900    0.9260
  *Enterococcus spp.* (HLAR)              0      0.00%    6                   1.52%    6     −2.4700   0.0140
  *Escherichia coli*                      3      3.23%    23                  5.82%    26    −1.1900   0.2330
  *Hemophilus influenzae*                 0      0.00%    1                   0.25%    1     −1.0000   0.3170
  *Klebsiella oxytoca*                    1      1.08%    2                   0.51%    3     0.5000    0.4700
  *Klebsiella pneumoniae*                 31     33.33%   68                  17.22%   99    3.0700    0.0020
  *Listeria monocytogenes*                0      0.00%    1                   0.25%    1     −1.0000   0.3170
  *Morganella morganii*                   1      1.08%    1                   0.25%    2     0.7500    0.4540
  *Neisseria meningitidis*                0      0.00%    1                   0.25%    1     −1.0000   0.3170
  *Nonfermenting gram-negative Bacilli*   4      4.30%    29                  7.34%    33    −1.2300   0.2200
  *Proteus spp.*                          2      2.15%    3                   0.76%    5     0.8900    0.3750
  *Pseudomonas aeruginosa*                11     11.83%   39                  9.87%    50    0.5300    0.5940
  *Pseudomonas spp.*                      0      0.00%    0                   0.00%    0     NA        
  *Salmonella enteritidis*                0      0.00%    1                   0.25%    1     −1.0000   0.3170
  *Salmonella paratyphi*                  0      0.00%    3                   0.76%    3     −1.7400   0.0820
  *Salmonella typhi*                      0      0.00%    4                   1.01%    4     −2.0100   0.0440
  *Staphylococcus aureus* (MRSA)          2      2.15%    38                  9.62%    40    −3.5400   \< 0.001
  *Staphylococcus aureus* (MSSA)          2      2.15%    45                  11.39%   47    −4.2100   \< 0.001
  *Streptococcus pneumoniae*              0      0.00%    5                   1.27%    5     −2.2500   0.0240
  α-Hemolytic *Streptococcus spp.*        0      0.00%    11                  2.78%    11    −3.3600   0.0010
  β-Hemolytic *Streptococcus spp.*        0      0.00%    5                   1.27%    5     −2.2500   0.0240
                                          93     19.02%   395                 80.78%   488             

###### Drug sensitivity profile of gram-positive strains

  Drug              Overall GPC   *Enterococcus spp.*   *Enterococcus spp* . (HLAR)   MRSA   MSSA    *Streptococcus pneumoniae*   CoNS    α-Hemolytic *Streptococcus spp.*   *Neisseria meningitidis*
  ----------------- ------------- --------------------- ----------------------------- ------ ------- ---------------------------- ------- ---------------------------------- --------------------------
  Imipenem          85.7          90.9                  60.0                                                                                                                 
  Ciprofloxacin     57.3          58.3                  0.0                           39.6   76.3                                 50.0    100.0                              41.7
  Penicillin        29.6          35.7                  100.0                         10.3   100.0   80.0                         33.3    77.8                               81.8
  Ampicillin        71.4          68.4                  50.0                                 100.0                                        81.8                               
  Vancomycin        96.5          100.0                 87.5                          96.3           100.0                        100.0   100.0                              
  Linezolid         90.2          90.0                  100.0                         96.3           100.0                        66.7                                       
  Gentamicin        79.8          86.7                  0.0                           65.3   97.9                                 80.0    80.0                               
  Tetracycline      74.8          42.9                  20.0                          83.3   87.2    50.0                         25.0    100.0                              
  Amikacin          68.9          0.0                   0.0                           85.7   100.0                                                                           
  Levofloxacin                    33.3                  0.0                           60.0   91.3    50.0                         100.0                                      
  Cefotaxime        67.8          100.0                 0.0                           23.1   90.0    75.0                         83.3    83.3                               
  Chloramphenicol   78.5                                50.0                          70.6   88.5    60.0                         50.0    100.0                              50.0
  Ofloxacin         61.4                                                              46.8   86.1                                 0.0                                        
  Netilmicin        85.9                                                              81.3   97.1                                                                            
  Rifampicin        48.6                                                              33.3           0.0                          0.0     100.0                              50.0
  Cephalexin        52.6                                                              10.5   100.0                                                                           
  Clindamycin                                                                         50.0                                                                                   
  Erythromycin      31.7                                                              7.9    47.1                                 40.0    100.0                              
  Ceftriaxone       45.3                                                              9.7    73.5    50.0                         50.0                                       66.7
  Cefepime                                                                            0.0    75.0    100.0                                                                   
  Azithromycin                                                                                                                                                               75.0
  Amoxicillin                                                                                        100.0                        100.0                                      
  Norfloxacin                                                                                                                     100.0                                      

###### Drug sensitivity profile of gram-negative bacilli strains

  Organism                    Ceftriaxone   Ceftazidime   Cefoperazone sulbactam   Cefoperazone   Cefotaxime   Piperacillin   Piperacillin-tazobactam   Imipenem   Meropenem   Levofloxacin   Ciprofloxacin   Ofloxacin   Ampicillin   Gentamicin   Amikacin   Chloramphenicol   Colistin   Cefepime
  --------------------------- ------------- ------------- ------------------------ -------------- ------------ -------------- ------------------------- ---------- ----------- -------------- --------------- ----------- ------------ ------------ ---------- ----------------- ---------- ----------
  Overall GNB                 23.8          19.2          83.1                     38.3           26.4         30.7           69.6                      86.9       89.1        68.7           48.6            59.3        10.8         58.0         63.0                                    19.4
  *Acinetobacter baumannii*   19.6          12.6          79.1                                    27.7         35.3           62.8                      78.4       100.0       65.7           58.6            60.8                     64.9         43.8       45.5              16.7       30.8
  *Acinetobacter lwoffii*     20.0          23.5          66.7                     100.0          25.0         26.7           50.0                      68.2       66.7        77.8           63.6            87.5                     76.5         71.4       66.7                         
  *Escherichia coli*          20.0          21.9          92.0                                    11.8         17.2           79.3                      100.0      100.0       16.7           15.4            20.0        9.4          86.2         85.7       100.0                        
  *Klebsiella pneumoniae*     10.6          7.2           81.6                     0.0            14.1         9.7            73.6                      98.4       93.8        66.7           39.7            59.1        2.9          55.0         61.5       76.0              40.0       12.5
  *Klebsiella oxytoca*        0.0           0.0           100.0                                                0.0            60.0                      100.0                  75.0                           66.7        0.0          0.0          50.0       50.0                         
  *Pseudomonas aeruginosa*    23.3          28.8          80.8                     44.8           50.0         52.8           68.9                      83.9       63.6        71.4           37.2            40.0                     34.0         65.0                         44.4       22.2
  *Nonfermenter GNB*          50.0          56.0          96.2                     25.0           69.2         66.7           88.9                      66.7       87.5        87.5           86.4            85.2        37.9         73.1                    100.0             100.0      0.0
  *Enterobacter spp.*         30.0          18.2          83.3                                    25.0         27.8           72.0                      96.0       83.3        83.3           66.7            78.9        4.8          30.4         66.7       20.0              100.0      0.0
  *Citrobacter spp.*                        28.6          100.0                                   0.0          42.9           42.9                      100.0                                 40.0            50.0                     50.0         50.0       50.0                         0.0
  *Proteus spp.*              25.0          0.0           100.0                                                20.0           20.0                      20.0                                  80.0            80.0                     75.0                                                 
  *Morganella morganii*                     0.0           100.0                                   0.0          0.0            100.0                     100.0                                 0.0             0.0                      50.0                                                 
  *Haemophilus influenzae*                                                                        100.0        100.0                                                           100.0                                      100.0                                100.0                        100.0
  *Salmonella spp.*           100.0         100.0         100.0                                   100.0        100.0          100.0                     100.0      100.0       100.0          100.0           100.0       88.9                                 100.0                        

Beta lactams proved least effective for GPCs with sensitivity lowest in penicillin (29.6%), ceftriaxone (45.6%), and cephalexin (52.6%). Erythromycin (31.7%) and rifampicin (48.6%) were largely ineffective. Relative sensitivity was highest for vancomycin (96.5%) and linezolid (90.2%). Even broad-spectrum antibiotics like chloramphenicol (78.5%) and tetracycline (74.8%) had good sensitivity against GPCs, especially MRSA. MSSA isolates uniformly showed very high sensitivities of \> 85% to ampicillin, gentamicin, amikacin, tetracycline, chloramphenicol, levofloxacin, and cefotaxime. *Streptococcus pneumoniae* showed an incredibly good sensitivity to amoxicillin (100%), cefepime (100%), and penicillin (80%).

*Neisseria meningitidis* isolates showed high sensitivity to penicillin (81.8%), azithromycin (75%), and ceftriaxone (66.67%). Interestingly, ciprofloxacin (41.67%) was only moderately effective. This is important because ciprofloxacin was the antimicrobial initially used to control the outbreak and also for the prophylaxis of contacts.

For GNBs, carbapenems were the most effective drugs (approximately \> 85% sensitivity). Cefoperazone-sulbactam (CFS, 83.1%) was the only other drug with sensitivity ≥80%. Quinolones were much less effective. Injectables like gentamicin (58%) and amikacin (63%) showed moderate sensitivity. Cephalosporins were mostly ineffective with sensitivities as low as 10%. *K. pneumoniae* and *E. coli* were highly susceptible to carbapenems (≥95% sensitivity) and CFS. *E. coli* additionally had better susceptibility (≥85%) against aminoglycosides too. Quinolones were moderately effective for *Klebsiella spp* . (60--75% sensitivity) but serve as very poor drugs to treat *E. coli* (15--20% sensitivity) BSIs. *A. baumannii* was most sensitive to carbapenems, CFS, moderately sensitive to quinolones, gentamicin, piperacillin-tazobactam. However, *Acinetobacter lwoffii* documented better sensitivity to aminoglycosides and quinolones compared with carbapenems. *P. aeruginosa* isolated in 14.4% BSIs, was better managed with imipenem, CFS (\> 80% sensitivity), piperacillin-tazobactam, and levofloxacin, whereas typical antipseudomonal drugs like cefoperazone and ceftazidime were largely ineffective. Nonfermenting GNBs (other than *Acinetobacter* and *Pseudomonas spp* .) were highly susceptible to quinolones, meropenem, CFS, piperacillin-tazobactam, and chloramphenicol. Imipenem and gentamicin were drugs which were moderately sensitive to these organisms. *Morganella, Salmonella,* and *Hemophilus spp* . isolates recovered were completely susceptible to usual drugs tested and no major antimicrobial resistance trends were observed in them.

Discussion
==========

BSI constitutes one of the major causes of morbidity and mortality. Definitive diagnosis is established by bacteriologic culture of blood samples to identify organisms and provide antimicrobial susceptibility. [@JR_10] Numerous analyses have concluded that early treatment of bacteremic patients with an appropriate antimicrobial drug improves survival. [@JR_11] [@JR_12] [@JR_13] [@JR_14] There exists a strong relationship between delay in effective initiation of therapy and in-hospital mortality of septic shock. Each hour of delay in therapy initiation is associated with an average decrease in survival of 8%. [@JR_15] Defining pathogen distribution and drug resistance patterns provides basis for empirical as well as definitive therapy. [@JR_16] This present study is an attempt to analyze the bacterial profile of blood culture isolates, assess antimicrobial trends, correlate bacteremic source and their impact, and discuss other variables which may help us devise the best ways of managing BSIs.

This is a 5-year retrospective analysis of 5,867 blood samples received from clinically suspected bacteremia patients. A total of 658 recognized pathogens were recovered from 637 specimens. A total of 97% isolates had monomicrobial growths. The rate of isolation for blood culture pathogens was observed at 11.2%. This is significant considering it is a new tertiary level 450-bedded hospital apart from the fact that the laboratory uses conventional blood culture bottles with no provision for continuous monitoring of culture bottles. Besides, this rate of isolation is in consonance with many studies from India [@JR_17] [@JR_18] [@JR_19] [@JR_20] [@JR_21] [@JR_22] and abroad. [@JR_23] [@JR_24] [@JR_25]

Although the mean age of bacteremic patients in the present study was 33.7 years, the highest number of cases of sepsis and shock were observed in children younger than 5 years age group as well as adults from 21 to 40 years age bracket. After the age of 40 years, the incidence of bacteremia cases shows a steady decline with every passing decade. Neonates, infants, and young children are particularly vulnerable to BSI owing to numerous risk factors like premature rupture of membrane, prolonged rupture, prematurity, recurrent urinary tract infection, poor maternal nutrition, low birthweight, birth asphyxia, congenital anomalies, and nascent/weak host immunity. [@JR_10]

Almost 31% of all medical ICU patients suspected with bacteremia were confirmed by culture. This is understood as patients admitted in ICU are usually already severely ill who are put under continued and enhanced vigilant care. Since they are better equipped to handle such serious infections, critical patients are referred to ICUs more frequently from other departments which explains the highest positivity yield of blood culture specimens received from medical ICU.

The rate of contamination observed (1.21%) is below the target level suggested by Hall and Lyman. [@JR_7] This correlates well with other studies by Archibald et al [@JR_26] and Weinstein. [@JR_9] These included mainly isolates of *Bacillus spp. Corynebacterium spp.,* and *Micrococcus spp* .

Among 658 pathogens isolated, GNB were significantly the predominant organisms. This corresponds to findings documented by other similar studies. [@JR_10] [@JR_17] [@JR_21] *Klebsiella spp* . as a dominant microbe causing BSIs was also reported by Roy et al [@JR_21] and Tariq. [@JR_23]

Within GPCs, *S. aureus* (65.6%) 'was the predominant pathogenic organism isolated.' Pre-eminence of *S. aureus* as a bloodstream pathogen has been documented by numerous similar studies. [@JR_10] [@JR_18] [@JR_25] [@JR_27] If a comparison of methicillin sensitivity is attempted among *S. aureus* strains, 52.34% were MSSA and rest were MRSA. MRSA are notorious since these are resistant to action of a broad group of β-lactam antibiotics, which cannot be used for therapy. One-third (10/30) of *Enterococcus spp* . isolates carried genes for HLAR, where a combination of β-lactams and aminoglycosides may not work in vivo for therapy even though they may have been sensitive in vitro. Coagulase negative *Staphylococcus* (CoNS), long considered as contaminants in 1970s and 1980s are nowadays considered to be agents capable of causing bacteremia. They are mostly incriminated as nosocomial pathogens specifically in catheter-related BSI. In fact, two studies [@JR_17] [@JR_28] reported CoNS as the most common isolate causing BSIs in ICU patients. Seven such isolates of CoNS were recovered in the present study which fulfilled the criteria for sepsis.

All patients with fungemia were critical and under observation in different ICUs. Risk factors for fungemia include prolonged hospital stay, hyper alimentation, previous broad-spectrum antimicrobial therapy, and ulcerations in gastrointestinal mucosa. Prognosis in fungemia patients is relatively poor. [@JR_29]

Frequency of isolation on different days of incubation within the 7-day incubation period reveals interesting trends. Most of the prominent isolates had a peak of detection on the second day of incubation which gradually tapered within the next 2 days. However, there was no significant difference observed between organisms isolated within the first 48 hours or beyond initial 48 hours.

An attempt was made to evaluate any correlation between the source of blood collection and the frequency of organisms isolated. The data for this information were available roughly for approximately 3 years (2011--2013) only. Chances of recovery of positive blood culture isolates from central line catheters were significantly higher in *A. baumannii* ( *p* \< 0.0029) and *K. pneumoniae* ( *p* \< 0.002). This is easily comprehensible since central venous catheters are kept in situ for longer durations compared with peripherally inserted catheters. These organisms are known to produce biofilm which improves their persistence within intravascular devices. Biofilm formation also imparts them the ability to reduce their metabolism rate, prevent antibiotic entry, and promote transfer of resistance plasmids. Such foci of bacteria can lead to sustained bacteremia if not dislodged in time, or catheter being removed. Contamination rates were similar for both sources of blood collection at approximately 1%. A study by Beutz et al [@JR_30] claims sensitivity of 92.5 and 95.9% for blood cultures drawn from central vein catheters and peripheral venipuncture, respectively. Even though the negative predictive values of both sources of blood collection was \> 95%, positive predictive values of blood cultures were low at 58.3 and 66.7%, respectively.

Beta lactam drugs are rapidly becoming ineffective for treating BSIs because of its indiscriminate and nonjudicious usage. Vancomycin, linezolid, aminoglycosides, and broad-spectrum drugs like chloramphenicol and tetracycline are the most reliable treatment options for GPCs, whereas carbapenems, CFS, aminoglycosides, and quinolones are remaining treatment options for GNBs. Aminoglycosides are good options for *E. coli* but not *K. pneumoniae* BSIs, while the opposite is true for quinolones. Cephalosporins and typical antipseudomonal drugs failed terribly in controlling concerned BSIs. Hence rationalized drug therapy is the call of the hour and therefore, studies of this type are quite warranted. De-escalation of high-end antimicrobials once actual sensitivity pattern is known contributes to reduction of antimicrobial pressure. Poor infection control practices and inappropriate use of antibiotics are main driving forces for the spread of resistant organisms. Aggressive measures like routine surveillance cultures to identify and isolate carriers, control of environmental sources, antibiotic restriction, antibiotic recycling, recommending combination therapy, implementing proper aseptic techniques, performing hand hygiene, maintaining robust infection control practices, and periodical assessment of antimicrobial policy will go a long way in preventing emergence of resistant organisms.

Conclusion
==========

Successful treatment of sepsis cases hinges on early diagnosis and proper antimicrobial therapy. The choice of antibiotics is based upon local knowledge of bacteriological profile and antimicrobial sensitivity patterns. The serious nature of the BSIs underscores the importance of periodic epidemiological surveillance studies such as the current one to provide useful insights for rational policy development and management of similar infections.
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